CASI Pharmaceuticals, Inc (DE) Annual Operating Income (Loss) in USD from 2018 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CASI Pharmaceuticals, Inc (DE) quarterly/annual Operating Income (Loss) history and growth rate from 2018 to 2022.
  • CASI Pharmaceuticals, Inc (DE) Operating Income (Loss) for the quarter ending December 31, 2022 was -$12.6M, a 14.4% decline year-over-year.
  • CASI Pharmaceuticals, Inc (DE) Operating Income (Loss) for the twelve months ending December 31, 2022 was -$34M, a 18% increase year-over-year.
  • CASI Pharmaceuticals, Inc (DE) annual Operating Income (Loss) for 2022 was -$34M, a 18% increase from 2021.
  • CASI Pharmaceuticals, Inc (DE) annual Operating Income (Loss) for 2021 was -$41.5M, a 21.3% increase from 2020.
  • CASI Pharmaceuticals, Inc (DE) annual Operating Income (Loss) for 2020 was -$52.8M, a 12.4% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$34M +$7.48M +18% Jan 1, 2022 Dec 31, 2022 20-F 2023-04-26
2021 -$41.5M +$11.3M +21.3% Jan 1, 2021 Dec 31, 2021 20-F 2023-04-26
2020 -$52.8M -$5.82M -12.4% Jan 1, 2020 Dec 31, 2020 20-F 2023-04-26
2019 -$47M -$19.8M -72.7% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-30
2018 -$27.2M Jan 1, 2018 Dec 31, 2018 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.